Evidence map›Paper›PMID 42256278›Full record

ArticleiScience2026

Inhibition of soluble epoxide hydrolase ameliorates renal injury in IgA nephropathy by restoring epoxyeicosatrienoic acids.

Hou-Hua Yin, Xian Fu, Qing Qiao, Enqin Yang, Ya-Nan Liu, Ying Bai, Ling Huang, Yi-Yu Chen, Zhu-Ying Huang, Di-Chun Yu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hou-Hua YinCNTTI of College of Pharmacy & Anesthesia Department of the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Xian FuCNTTI of College of Pharmacy & Anesthesia Department of the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Qing QiaoThe Department of Nephrology, the Fourth Affiliated Hospital of Soochow University, Suzhou 215125, China.
Enqin YangBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Ya-Nan LiuBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Ying BaiBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Ling HuangBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Yi-Yu ChenBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Zhu-Ying HuangBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Di-Chun YuBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Ping DaiBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Qing-Jin PanBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Yi-Wen MengBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Si-Yi YinBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Xiao LiuBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Shenyou NieBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Bing-Qing DengThe Department of Nephrology, the Fourth Affiliated Hospital of Soochow University, Suzhou 215125, China.
Yi HeBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (CNTTI), Ministry of Education, Chongqing 400016, China.
Jun-Yan LiuCNTTI of College of Pharmacy & Anesthesia Department of the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin A (IgA) nephropathy (IgAN) is a major cause of end-stage renal disease with limited therapies. Altered lipid metabolism is implicated in chronic kidney disease, but its role in IgAN is unclear. Plasma oxylipin profiling and renal single-cell RNA sequencing (scRNA-seq) revealed reduced epoxyeicosatrienoic acids (EETs) and increased soluble epoxide hydrolase (sEH) in IgAN. Two sEH inhibitors,

Indexed as

molecular biologynephrologysmall moleculetherapeutics

Identifiers

PMID42256278
PMCPMC13233579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.